|
ADA
Jun 21, 2018 22:14:52 GMT -5
via mobile
Post by bones1026 on Jun 21, 2018 22:14:52 GMT -5
Temper expectations—but it will be a shock?
|
|
|
Post by mytakeonit on Jun 21, 2018 23:44:33 GMT -5
Probably just finishing up from the night before ... the Guiness I mean.
|
|
|
Post by pguererro on Jun 22, 2018 13:35:06 GMT -5
Temper expectations—but it will be a shock? Can we all just say what we want to say about the poster. Massive disappointment.....61% vs 55%. This is what we’ve been waiting for 6 mos? There’s going to be some positive take aways from the trial to share, however, I like a few others have posted, was expecting to see the Dexcom readings my colleagues with Type 1 have shown me. Just extremely disappointed. Endos will not bat an eye at that TIR data, especially from 15 patients. Unbelievable. Truly crushed by these numbers.
|
|
|
Post by joeypotsandpans on Jun 22, 2018 14:36:28 GMT -5
Temper expectations—but it will be a shock? Can we all just say what we want to say about the poster. Massive disappointment.....61% vs 55%. This is what we’ve been waiting for 6 mos? There’s going to be some positive take aways from the trial to share, however, I like a few others have posted, was expecting to see the Dexcom readings my colleagues with Type 1 have shown me. Just extremely disappointed. Endos will not bat an eye at that TIR data, especially from 15 patients. Unbelievable. Truly crushed by these numbers. Two questions, have you heard your CMO speak yet (in depth) since he arrived at the company and what is the minimum percentage difference that you would take as statistically significant? I understand you're coming at it from the sales side but obviously as a user and personally having a significant drop in my A1c after using other methods/treatments that couldn't deliver anywhere close to what Afrezza has I think you should temper your disappointment. Also the acceptance of the late breaker session regarding lower hypo's is very important as well. I sure hope as a salesperson that you aren't one of those that walks into the office already defeated ....I know my rep doesn't and has a great outlook especially having come from Dexcom. BOL to you going forward.
|
|
|
Post by brotherm1 on Jun 22, 2018 15:27:38 GMT -5
even just on the face of it alone, I’d personally be glad to jump on an 11% improvement
|
|
|
ADA
Jun 22, 2018 16:11:43 GMT -5
Post by agedhippie on Jun 22, 2018 16:11:43 GMT -5
Temper expectations—but it will be a shock? Can we all just say what we want to say about the poster. Massive disappointment.....61% vs 55%. This is what we’ve been waiting for 6 mos? There’s going to be some positive take aways from the trial to share, however, I like a few others have posted, was expecting to see the Dexcom readings my colleagues with Type 1 have shown me. Just extremely disappointed. Endos will not bat an eye at that TIR data, especially from 15 patients. Unbelievable. Truly crushed by these numbers. The real problem is that 61% for compliant patients is not great. The Medtronics 670G pump will do 72% TIR in auto mode (initially the 670G was hitting 87% TIR but compliance dropped and it finally settled at 72%). The TIR for non-compliant Afrezza patients is going to be a problem.
|
|
|
ADA
Jun 22, 2018 16:54:30 GMT -5
via mobile
Post by brotherm1 on Jun 22, 2018 16:54:30 GMT -5
What % of PWD’s have or want pumps?
|
|
|
ADA
Jun 22, 2018 16:57:29 GMT -5
Post by brianrocco on Jun 22, 2018 16:57:29 GMT -5
Does this study also explain why many who have tried Afrezza have not been continuing with the product? Per Figures 1c and 1d the non-compliant Afrezza users had higher BG and were out of range longer than non-Afrezza users.
|
|
|
ADA
Jun 22, 2018 17:49:02 GMT -5
via mobile
Post by brotherm1 on Jun 22, 2018 17:49:02 GMT -5
Can we all just say what we want to say about the poster. Massive disappointment.....61% vs 55%. This is what we’ve been waiting for 6 mos? There’s going to be some positive take aways from the trial to share, however, I like a few others have posted, was expecting to see the Dexcom readings my colleagues with Type 1 have shown me. Just extremely disappointed. Endos will not bat an eye at that TIR data, especially from 15 patients. Unbelievable. Truly crushed by these numbers. The real problem is that 61% for compliant patients is not great. The Medtronics 670G pump will do 72% TIR in auto mode (initially the 670G was hitting 87% TIR but compliance dropped and it finally settled at 72%). The TIR for non-compliant Afrezza patients is going to be a problem. Where’d you go? You got a kink in your canula? What % of PWD’s have or want a pump?
|
|
|
ADA
Jun 22, 2018 17:56:42 GMT -5
Post by pantaloons on Jun 22, 2018 17:56:42 GMT -5
Can anyone comment on the statistical power of the study and type I error for this analysis? I think there is something to be said about the sample size and absolute difference in means between the treatment groups. Statistical significance may or may not be real. I think follow up studies will be key here, and I'm hoping Dr. Kendall will be able to design future studies to continue to convince endocrinologists of Afrezza's value. TIA.
|
|
|
Post by peppy on Jun 22, 2018 17:58:05 GMT -5
The real problem is that 61% for compliant patients is not great. The Medtronics 670G pump will do 72% TIR in auto mode (initially the 670G was hitting 87% TIR but compliance dropped and it finally settled at 72%). The TIR for non-compliant Afrezza patients is going to be a problem. Where’d you go? You got a kink in your canola? What % of PWD’s have or want a pump? allow me to say, aged has a pump and does not use it. additionally aged has a dexcom and he is not using it. Diabetes sucks. I have been reading aged for years. Every time I have asked aged what his blood glucose level is, it has always been ~ 98 mg/dl. hi aged.
|
|
|
Post by sayhey24 on Jun 22, 2018 18:33:23 GMT -5
Temper expectations—but it will be a shock? Can we all just say what we want to say about the poster. Massive disappointment.....61% vs 55%. This is what we’ve been waiting for 6 mos? There’s going to be some positive take aways from the trial to share, however, I like a few others have posted, was expecting to see the Dexcom readings my colleagues with Type 1 have shown me. Just extremely disappointed. Endos will not bat an eye at that TIR data, especially from 15 patients. Unbelievable. Truly crushed by these numbers. Let me help you feel a little better. If you look at the TIR graph for the compliant group, what percentage of time is the PWD in range during the hours of 8am to 8pm? It looks to me to be 100%. Thats the active time range for afrezza's use. Thats the time range when afrezza will be effecting BG levels.
I could be wrong but I don't think you can do better than 100%. IMO, thats pretty damn good, maybe even amazing.
The hours of 8pm to 8am is the job of the basal. With the 33% fewer serious hypos, in clinical practice the basal would be increased which would reduce the target baseline which would provide even better overall TIR than the 61%. Some might even split doses and knowing they won't go low from the afrezza they have more freedom for night time dosing.
I think afrezzauser splits his basal. Doing this I think you might even beat Aged's medtronic pumps 72%. Then again adding the afrezza with the pump would even provide the potential for even better numbers.
|
|
|
Post by agedhippie on Jun 22, 2018 18:59:11 GMT -5
The real problem is that 61% for compliant patients is not great. The Medtronics 670G pump will do 72% TIR in auto mode (initially the 670G was hitting 87% TIR but compliance dropped and it finally settled at 72%). The TIR for non-compliant Afrezza patients is going to be a problem. Where’d you go? You got a kink in your canula? What % of PWD’s have or want a pump? Looks like there were stats from 2015 that put the number around 30%, but there are later ones at 59% (which I think is high). The real data is in expensive reports.
|
|
|
Post by sportsrancho on Jun 22, 2018 19:00:10 GMT -5
The real problem is that 61% for compliant patients is not great. The Medtronics 670G pump will do 72% TIR in auto mode (initially the 670G was hitting 87% TIR but compliance dropped and it finally settled at 72%). The TIR for non-compliant Afrezza patients is going to be a problem. Where’d you go? You got a kink in your canula? What % of PWD’s have or want a pump? Roughly one million people use insulin pumps (continuous subcutaneous insulin infusion) worldwide, and more than 200 million people worldwide have been diagnosed with diabetes. Most people who use insulin pumps have type 1 diabetes, though some people with type 2 diabetes also use them. www.diabetes.org/newsroom/press-releases/2015/insulin-pumps.html
|
|
Deleted
Deleted Member
Posts: 0
|
ADA
Jun 22, 2018 19:00:50 GMT -5
via mobile
Post by Deleted on Jun 22, 2018 19:00:50 GMT -5
What is the HbA1c for both groups? That was supposed to be a secondary end-point.
|
|